journal article
Open Access
Jul 10, 2024
Burden of gout among different WHO regions, 1990–2019: estimates from the global burden of disease study
Abstract
AbstractThe global incidence of gout has increased rapidly, likely secondary to the increase in the prevalence of conditions that predispose to gout, such as obesity. Depending on the population studied, the prevalence of gout ranges from less than 1 to 6.8%. Thus, gout can be a significant burden on healthcare systems. The objective of this study is to observe the trends in the incidence, prevalence, and disability-adjusted life years (DALYs) of gout between 1990 and 2019 globally and in the European Union (EU) 15+ nations. We extracted data from the Global Burden of Disease Study database based on the International Classification of Diseases (ICD) versions 10 and 9. Incidence, prevalence, and disability-adjusted life years (DALYs) were extracted for individual EU15+ countries and globally in males and females between 1990 and 2019. Joinpoint regression analysis was used to describe trends. Between 1990 and 2019, gout prevalence, incidence, and DALYs increased in both males (+ 21.42%, + 16.87%, + 21.49%, respectively) and females (+ 21.06%, + 18.75%, + 20.66%, respectively) globally. The United States of America had the highest increase in prevalence (males: + 90.6%; females + 47.1%), incidence (males: + 63.73%; females: + 39.11%) and DALYs (males: + 90.43%; females: + 42.75%). Incidence, prevalence, and DALYs from gout are increasing worldwide and in most of the EU15+ countries for males and females. Studies have reported the association of gout with comorbidities such as metabolic syndrome, diabetes mellitus, and cardiovascular disease. Health policies and resource allocation are required to increase awareness and modify risk factors globally.
Topics
No keywords indexed for this article. Browse by subject →
References
38
[1]
Dehlin, M., Jacobsson, L. & Roddy, E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 16(7), 380–390 (2020).
10.1038/s41584-020-0441-1
[2]
MacFarlane, L. A. & Kim, S. C. Gout: A review of nonmodifiable and modifiable risk factors. Rheum. Dis. Clin. North Am. 40(4), 581–604 (2014).
10.1016/j.rdc.2014.07.002
[3]
Eliseev, M. S. & Novikova, A. M. Comorbidity in gout and hyperuricemia: Prevalence, causes, prospects of urate lowering therapy. Ter. Arkh. 91(5), 120–128 (2019).
[4]
Wijnands, J. M. et al. Determinants of the prevalence of gout in the general population: A systematic review and meta-regression. Eur. J. Epidemiol. 30(1), 19–33 (2015).
10.1007/s10654-014-9927-y
[5]
Lim, S. Y. et al. Trends in gout and rheumatoid arthritis hospitalizations in the United States, 1993–2011. Jama 315(21), 2345–2347 (2016).
10.1001/jama.2016.3517
[6]
Rai, S. K. et al. Trends in gout and rheumatoid arthritis hospitalizations in Canada from 2000 to 2011. Arthr. Care Res 69(5), 758–762 (2017).
10.1002/acr.23012
[7]
Kiadaliri, A. A. & Englund, M. Temporal trends and regional disparity in rheumatoid arthritis and gout hospitalizations in Sweden, 1998–2015. Clin. Rheumatol. 37(3), 825–830 (2018).
10.1007/s10067-018-3983-8
[8]
Robinson, P. C., Merriman, T. R., Herbison, P. & Highton, J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999–2009. Rheumatology 52(1), 118–126 (2013).
10.1093/rheumatology/kes253
[9]
Lottmann, K., Chen, X. & Schädlich, P. K. Association between gout and all-cause as well as cardiovascular mortality: A systematic review. Curr. Rheumatol. Rep. 14(2), 195–203 (2012).
10.1007/s11926-011-0234-2
[10]
Salciccioli, J. D. et al. Respiratory disease mortality in the United Kingdom compared with EU15+ countries in 1985–2015: Observational study. Bmj. 363, k4680 (2018).
10.1136/bmj.k4680
[11]
Goodall, R., Salciccioli, J. D., Davies, A. H., Marshall, D. & Shalhoub, J. Trends in peripheral arterial disease incidence and mortality in EU15+ countries 1990–2017. Eur. J. Prev. Cardiol. 28(11), 1201–1213 (2021).
10.1177/2047487319899626
[12]
Al-Balah, A., Goodall, R., Salciccioli, J. D., Marshall, D. C. & Shalhoub, J. Mortality from abdominal aortic aneurysm: Trends in European Union 15+ countries from 1990 to 2017. Br. J. Surg. 107(11), 1459–1467 (2020).
10.1002/bjs.11635
[13]
Schuster-Bruce, J. et al. A Comparison of the burden of thyroid cancer among the European Union 15+ countries, 1990–2019: Estimates from the global burden of disease study. JAMA Otolaryngol. Head Neck Surg. 148(4), 350–359 (2022).
10.1001/jamaoto.2021.4549
[14]
Mikkelsen, L. et al. A global assessment of civil registration and vital statistics systems: Monitoring data quality and progress. Lancet 386(10001), 1395–1406 (2015).
10.1016/s0140-6736(15)60171-4
[15]
Fitzmaurice, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 5(12), 1749–1768 (2019).
10.1001/jamaoncol.2019.2996
[16]
Kilfoy, B. A. et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 20(5), 525–531 (2009).
10.1007/s10552-008-9260-4
[17]
The 2019 Global Burden of Disease (GBD) study results. https://vizhub.healthdata.org/gbd-results/
[18]
World Population Prospects. The 2012 Revision. Highlights and Advance Tables. https://population.un.org/wpp/publications/Files/WPP2012_HIGHLIGHTS.pdf. Access date: 09/22/2022.
[19]
WHO Global Health Estimates: Life expectancy and leading causes of death and disability. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates. Access date 09/22/2022.
[20]
Kim, H. J., Fay, M. P., Feuer, E. J. & Midthune, D. N. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19(3), 335–351 (2000).
10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z
[21]
Safiri, S. et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990–2017: A systematic analysis of the global burden of disease study 2017. Arthr. Rheumatol. 72(11), 1916–1927 (2020).
10.1002/art.41404
[22]
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
Kitty J. Jager, Csaba Kovesdy, Robyn Langham et al.
Kidney International
2019
10.1016/j.kint.2019.07.012
[23]
Kovesdy, C. P. Epidemiology of chronic kidney disease: An update 2022. Kidney Int. Suppl. 12(1), 7–11 (2022).
10.1016/j.kisu.2021.11.003
[24]
WHO Regional Office for Europe. WHO European Regional Obesity Report 2022. World Health Organization. 2022.
[25]
Saklayen, M. G. The global epidemic of the metabolic syndrome. Curr. Hypertens. Rep. 20(2), 12 (2018).
10.1007/s11906-018-0812-z
[26]
Rho, Y. H., Zhu, Y. & Choi, H. K. The epidemiology of uric acid and fructose. Semin. Nephrol. 31(5), 410–419 (2011).
10.1016/j.semnephrol.2011.08.004
[27]
Kretowicz, M., Johnson, R. J., Ishimoto, T., Nakagawa, T. & Manitius, J. The impact of fructose on renal function and blood pressure. Int. J. Nephrol. 2011, 315879 (2011).
10.4061/2011/315879
[28]
Yokose, C. et al. Trends in prevalence of gout among US asian adults, 2011–2018. JAMA Netw. Open 6(4), e239501-e (2023).
10.1001/jamanetworkopen.2023.9501
[29]
McCormick, N. et al. Racial and sex disparities in gout prevalence among US adults. JAMA Netw. Open. 5(8), e2226804 (2022).
10.1001/jamanetworkopen.2022.26804
[30]
Katzmarzyk, P. T., Church, T. S., Janssen, I., Ross, R. & Blair, S. N. Metabolic syndrome, obesity, and mortality: Impact of cardiorespiratory fitness. Diabetes Care 28(2), 391–397 (2005).
10.2337/diacare.28.2.391
[31]
DeMarco, V. G., Aroor, A. R. & Sowers, J. R. The pathophysiology of hypertension in patients with obesity. Nat. Rev. Endocrinol. 10(6), 364–376 (2014).
10.1038/nrendo.2014.44
[32]
FitzGerald, J. D. et al. 2020 American college of rheumatology guideline for the management of gout. Arthr. Care Res. 72(6), 744–760 (2020).
10.1002/acr.24180
[33]
Per capita health spending by country 2022 | Statista. (2023, September 19). Statista. https://www.statista.com/statistics/236541/per-capita-health-expenditure-by-country/#:~:text=health%20care%20services.-,Health%20Expenditure%20in%20the%20U.S.,percent%20by%20the%20year%202031.
[34]
Doghramji, P. P., Fermer, S., Wood, R., Morlock, R. & Baumgartner, S. Management of gout in the real world: Current practice versus guideline recommendations. Postgrad. Med. 128(1), 106–114 (2016).
10.1080/00325481.2016.1114878
[35]
Chen-Xu, M., Yokose, C., Rai, S. K., Pillinger, M. H. & Choi, H. K. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The national health and nutrition examination survey, 2007–2016. Arthr. Rheumatol. 71(6), 991–999 (2019).
10.1002/art.40807
[36]
Mahajan, A., Tandon, V., Sharma, S., Jandial, C. Gout and menopause. (2007).
[37]
Bruderer, S. G., Bodmer, M., Jick, S. S. & Meier, C. R. Association of hormone therapy and incident gout: population-based case-control study. Menopause 22(12), 1335–1342 (2015).
10.1097/gme.0000000000000474
[38]
Global Burden of Disease Study 2017 (GBD 2017) Causes of Death and Nonfatal Causes Mapped to ICD Codes. https://ghdx.healthdata.org/record/ihme-data/gbd-2017-cause-icd-code-mappings. Access date: 09/22/2022.
Metrics
20
Citations
38
References
Details
- Published
- Jul 10, 2024
- Vol/Issue
- 14(1)
- License
- View
Authors
Cite This Article
Shoheera Punjwani, Chinmay Jani, Weitao Liu, et al. (2024). Burden of gout among different WHO regions, 1990–2019: estimates from the global burden of disease study. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-61616-z
Related
You May Also Like
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Michiru Nishita, Seung-Yeol Park · 2017
16,078 citations
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
Antoine Daina, Olivier Michielin · 2017
14,446 citations
Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
Valentina Cappello, Laura Marchetti · 2016
13,254 citations
QuPath: Open source software for digital pathology image analysis
Peter Bankhead, Maurice B. Loughrey · 2017
7,659 citations
Lead Iodide Perovskite Sensitized All-Solid-State Submicron Thin Film Mesoscopic Solar Cell with Efficiency Exceeding 9%
Hui-Seon Kim, Chang-Ryul Lee · 2012
7,401 citations